Analysts Set Septerna, Inc. (NASDAQ:SEPN) Price Target at $26.75

Septerna, Inc. (NASDAQ:SEPN) has been given an average rating of “Moderate Buy” by the five research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $26.75.

Several equities research analysts have weighed in on the stock. Wall Street Zen cut shares of Septerna from a “hold” rating to a “sell” rating in a research report on Saturday. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of Septerna in a research report on Friday, September 5th. Wells Fargo & Company increased their target price on Septerna from $11.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Friday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $26.00 price target on shares of Septerna in a research report on Thursday, August 21st.

Institutional Trading of Septerna

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC purchased a new position in Septerna in the 4th quarter worth approximately $25,000. The Manufacturers Life Insurance Company purchased a new position in Septerna during the 4th quarter valued at $506,000. Northern Trust Corp purchased a new position in Septerna in the 4th quarter worth about $3,384,000. Jane Street Group LLC purchased a new stake in shares of Septerna in the fourth quarter valued at approximately $600,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Septerna during the fourth quarter valued at $52,000.

Septerna Stock Down 1.0%

SEPN opened at $14.28 on Wednesday. Septerna has a twelve month low of $4.17 and a twelve month high of $28.99. The stock has a market cap of $636.60 million and a price-to-earnings ratio of -1.42. The company’s 50-day moving average price is $12.47 and its two-hundred day moving average price is $9.41.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%.The firm had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $22.50 million. As a group, sell-side analysts anticipate that Septerna will post -7.11 earnings per share for the current year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.